Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
Status: | Recruiting |
---|---|
Conditions: | Cardiology, Ocular |
Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 5/10/2017 |
Start Date: | April 19, 2017 |
End Date: | September 2017 |
The protocol will measure a number of cytokines in addition to vascular endothelial growth
factor in response to 0.3mg Lucentis.
factor in response to 0.3mg Lucentis.
Lucentis injections are the current standard of care for diabetic macular edema. The only
deviation from the standard of care in the current protocol is an aqueous tap before the
first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.
deviation from the standard of care in the current protocol is an aqueous tap before the
first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.
Inclusion Criteria:
- Diagnosis of diabetes mellitus
- Best corrected visual acuity 20/32 - 20/320
- Diabetic macular edema involving the center of the macula
- Optical coherence tomography central subfield thickness of at least 250 microns
Exclusion Criteria:
- History of anti-vascular endothelial growth factor treatment in the past 12 months
- Any diabetic macular edema treatment in the past 4 months
- Heart attack, stroke, transient ischemic attack or acute congestive heart failure
within 4 months
We found this trial at
1
site
Grand Rapids, Michigan 49525
Principal Investigator: Louis C. Glazer, M.D.
Phone: 616-285-1200
Click here to add this to my saved trials